Dr. Dunsire has served as a member of the Ultragenyx board since April 2017. She served as president and chief executive officer of H. Lundbeck A/S from September 2018 until August 2023. She previously served as president and CEO and a director of Xtuit Pharmaceuticals, Inc., a private biopharmaceutical company, from January 2017 to March 2018. Prior to her position at Xtuit, she served as president and CEO and a director of FORUM Pharmaceuticals Inc., a private pharmaceutical company, from July 2013 to May 2016. Prior to FORUM, Dr. Dunsire worked for Takeda Pharmaceutical Company Limited as a corporate officer from June 2010 to June 2011 and a director from June 2011 to June 2013. She served as president, CEO and a director of Millennium Pharmaceuticals, Inc. between 2005 and 2008, when it was acquired by Takeda, and then as president and CEO of Millennium: The Takeda Oncology Company after the acquisition between 2008 and 2013. Prior to Millennium, Dr. Dunsire held various roles of increasing responsibility at Novartis Pharma AG between 1988 and 2005. She currently serves as a director of Syros Pharmaceuticals. Dr. Dunsire obtained an MBBCh from the University of the Witwatersrand.